Abstract
Congenital Disorders of Glycosylation (CDG) are a rapidly growing family of genetic and mostly multisystem diseases caused by defects in the biosynthesis of the glycan moiety of glycoconjugates such as glycoproteins. Since the description of the first patients by Jaeken et al. in 1980, 23 defects have been identified in N- and O-protein glycosylation: 18 defects in N- or N- and O-glycosylation (12 glycan assembly defects: CDG-Ia to CDG-IL; 6 glycan processing defects: CDG-IIa to CDG-IIf) and 5 defects in O-glycosylation. There is a rapidly growing number of patients with a putative CDG in whom the known defects have been excluded (CDG-x). This review focuses on recent developments in the field including advances in the biochemical and molecular diagnosis of CDG and new features of known CDG. It also deals with the identification of new protein glycosylation disorders, of the first lipid glycosylation disorder, and of the emerging group of hyperglycosylation disorders. Finally, we speculate about future developments.
Keywords: CDG, COG, hyperglycosylation, lipid glycosylation, protein glycosylation
Current Pediatric Reviews
Title: Congenital Disorders of Glycosylation (CDG): Update and Perspectives
Volume: 2 Issue: 4
Author(s): Renate Zeevaert, Els Schollen, Hubert Carchon, Gert Matthijs and Jaak Jaeken
Affiliation:
Keywords: CDG, COG, hyperglycosylation, lipid glycosylation, protein glycosylation
Abstract: Congenital Disorders of Glycosylation (CDG) are a rapidly growing family of genetic and mostly multisystem diseases caused by defects in the biosynthesis of the glycan moiety of glycoconjugates such as glycoproteins. Since the description of the first patients by Jaeken et al. in 1980, 23 defects have been identified in N- and O-protein glycosylation: 18 defects in N- or N- and O-glycosylation (12 glycan assembly defects: CDG-Ia to CDG-IL; 6 glycan processing defects: CDG-IIa to CDG-IIf) and 5 defects in O-glycosylation. There is a rapidly growing number of patients with a putative CDG in whom the known defects have been excluded (CDG-x). This review focuses on recent developments in the field including advances in the biochemical and molecular diagnosis of CDG and new features of known CDG. It also deals with the identification of new protein glycosylation disorders, of the first lipid glycosylation disorder, and of the emerging group of hyperglycosylation disorders. Finally, we speculate about future developments.
Export Options
About this article
Cite this article as:
Zeevaert Renate, Schollen Els, Carchon Hubert, Matthijs Gert and Jaeken Jaak, Congenital Disorders of Glycosylation (CDG): Update and Perspectives, Current Pediatric Reviews 2006; 2 (4) . https://dx.doi.org/10.2174/157339606778699699
DOI https://dx.doi.org/10.2174/157339606778699699 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prognostic Role of Sub-Clinical Hypothyroidism in Chronic Heart Failure Outpatients
Current Pharmaceutical Design Clinical Features and Disease Damage Risk Factors in an Egyptian SLE Cohort: A Multicenter Study
Current Rheumatology Reviews Curcumin and its Multi-target Function Against Pain and Inflammation: An Update of Pre-clinical Data
Current Drug Targets Sympathetic Activation in Congestive Heart Failure: Evidence, Consequences and Therapeutic Implications
Current Vascular Pharmacology Nanotechnology and Diabetic Wound Healing: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Myocardial Infarction with Non Obstructive Coronary Atherosclerosis: A Case Report
New Emirates Medical Journal The Involvement of PPARs in the Causes, Consequences and Mechanisms for Correction of Cardiac Lipotoxicity and Oxidative Stress
Current Molecular Pharmacology Autophagy Inhibition Rescues Against Leptin-Induced Cardiac Contractile Dysfunction
Current Pharmaceutical Design A Palliative Care Approach to the Advanced Heart Failure Patient
Current Cardiology Reviews Occurrence and Clinical Impact of Microembolic Signals (MES) in Patients with Chronic Cardiac Diseases and Atheroaortic Plaques - A Systematic Review
Current Vascular Pharmacology Maternal Sepsis 2010: Early Recognition and Aggressive Treatment with Early Goal Directed Therapy can Improve Maternal Outcomes
Current Women`s Health Reviews Relevance of Sphingolipids in the Pleiotropic Protective Effects of High-Density Lipoproteins
Current Pharmaceutical Design Current Status in Iron Chelation in Hemoglobinopathies
Current Molecular Medicine Meloxicam Prevents Load-Induced Cardiac Hypertrophy in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Lifestyle Changes and Surgical Treatment for Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Genetically Modified Endothelial Progenitor Cells in the Therapy of Cardiovascular Disease and Pulmonary Hypertension
Current Vascular Pharmacology Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology Cardiolipin Metabolism and the Role it Plays in Heart Failure and Mitochondrial Supercomplex Formation
Cardiovascular & Hematological Disorders-Drug Targets Obstetric Anaesthesia and Obesity
Current Women`s Health Reviews Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)
Current Gene Therapy